Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

PET FDG Assessment of Change in Atherosclerotic Plaques After Chemotherapy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2008 by Tel-Aviv Sourasky Medical Center.
Recruitment status was:  Not yet recruiting
Information provided by:
Tel-Aviv Sourasky Medical Center Identifier:
First received: August 25, 2008
Last updated: September 8, 2008
Last verified: August 2008
The purpose of this study is to determine whether chemotherapy induces regression in atherosclerotic plaques in oncologic patients already undergoing PET FDG as part of their routine assessment.We will use PET FDG to assess whether the inflammation in atherosclerotic plaques is affected by chemotherapy and anti angiogenic therapy.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Estimated Enrollment: 40
Study Start Date: September 2008
Breast cancer patients
Lung cancer patients


Ages Eligible for Study:   65 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Breast cancer patients at the Tel-Aviv Sourasky Medical Center Lung cancer patients at the Tel-Aviv Sourasky Medical Center

Inclusion Criteria:

  • Women over the age of 65 diagnosed with metastatic breast cancer
  • Men over the age of 65 diagnosed with lung cancer

Exclusion Criteria:

  • Patients under the age of 65
  • Patients diagnosed with chronic inflammatory disease or chronic infection
  • Patients taking steroids and NSAIDS on a regular basis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00742352

Contact: Einat Even Sapir, MD PhD 972-3-6973532

Tel-Aviv Sourasky Medical Center Not yet recruiting
Tel Aviv, Israel, 64239
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
  More Information

Responsible Party: Prof. Einat Even-Sapir, Tel-Aviv Sourasky Medical Center Identifier: NCT00742352     History of Changes
Other Study ID Numbers: TASMC-08-EES-253-CTIL
Study First Received: August 25, 2008
Last Updated: September 8, 2008

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases processed this record on April 28, 2017